Cover Image
Market Research Report

Alport Syndrome - Market Insights, Epidemiology, and Market Forecast - 2028

Published by DelveInsight Business Research LLP Product code 915408
Published Content info 160 Pages
Delivery time: 1-2 business days
Price
Back to Top
Alport Syndrome - Market Insights, Epidemiology, and Market Forecast - 2028
Published: November 1, 2019 Content info: 160 Pages
Description

DelveInsight's Alport Syndrome-Market Insights, Epidemiology, and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Alport syndrome for the emerging markets, i.e., Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alport syndrome from 2017 to 2028 segmented by ten emerging market. The report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Turkey
  • Russia
  • Colombia
  • Brazil
  • Argentina
  • Mexico
  • Saudi Arabia
  • UAE
  • Taiwan
  • China

Study Period: 2017-2028

Alport Syndrome - Disease Understanding and Treatment Algorithm

The DelveInsight Alport syndrome market report gives the thorough understanding of Alport syndrome by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease for the emerging markets, i.e., Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

Alport Syndrome - Epidemiology

The Alport syndrome epidemiology division provides the insights about historical and current patient pool and forecasted trend for all ten emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the total disease prevalence, diagnosed cases, treatable cases and prevalence based on clinical types and clinical manifestations in Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Alport syndrome in the ten emerging markets, i.e., Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China from 2017-2028.

According to DelveInsight, total prevalent population of Alport syndrome in ten emerging markets was found to be 187,718 in 2017.

Alport syndrome - Drug Chapters

This segment of the Alport syndrome report encloses the detailed analysis of the marketed and emerging drugs. It also helps to understand the product description, clinical development, clinical trial details, approvals and other regulatory milestones, and the latest news and press releases.

At present, therapeutic approach of Alport syndrome focuses on the off-label systemic therapies such as angiotensin-converting enzyme inhibition (ACEi) and angiotensin receptor blockers (ARB). However a small percentage of share is also taken by other medications such as aldosterone inhibitors, statins and cyclosporine. Currently, Bardoxolone Methyl, an experimental, oral, once-daily activator of nuclear factor erythroid 2-related factor 2 (Nrf2) by Reata Pharmaceuticals is in later stage of clinical studies and RG 012 by Sanofi has completed phase I of the clinical trial and has gained orphan drug designation by FDA and European Commission.

Alport syndrome - Market Outlook

The Alport syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.

This segment gives a thorough detail of marketed therapies and emerging therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Alport syndrome in the ten emerging market was found to be USD 6.57 million in 2017.

Alport syndrome - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alport syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alport syndrome Report Key Strengths

  • 10 Year Forecast
  • 10 emerging countries Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Market Size by Therapies
  • Key Cross Competition

Alport syndrome Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Alport syndrome market.
  • Organize sales and marketing efforts by identifying the best opportunities for Alport syndrome market.
  • To understand the future market competition in the Alport syndrome market.
Table of Contents
Product Code: DIMI0685

Table of Contents

1. Key Insights

2. Alport Syndrome: Epidemiology Overview at a Glance

  • 2.1. Total Prevalent Population of Alport Syndrome in 2017
  • 2.2. Total Prevalent Population of Alport Syndrome in 2028

3. Alport Syndrome: Market Overview at a Glance

  • 3.1. Total Market Share (%) Distribution of Alport Syndrome in 2017
  • 3.2. Total Market Share (%) Distribution of Alport Syndrome in 2028

4. Alport Syndrome: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Causes and Risk Factors
  • 4.3. Inheritance Pattern
  • 4.4. Signs and Symptoms
  • 4.5. Clinical Manifestations
    • 4.5.1. Renal Manifestations
    • 4.5.2. Audiological Manifestations
    • 4.5.3. Ophthalmological Manifestations
  • 4.6. Pathophysiology
  • 4.7. Diagnostic Approach

5. Treatment

  • 5.1. Current treatment for Alport Syndrome
  • 5.2. Future treatment for Alport Syndrome
  • 5.3. Treatment Algorithm

6. Unmet Needs

7. Organizations contributing toward Alport Syndrome

8. KOL's Views: Alport Syndrome

9. Key Cross Competitors

10. Marketed Drugs

  • 10.1. Bardoxolone Methyl: Reata Pharmaceuticals
    • 10.1.1. Product Description
    • 10.1.2. Clinical Development
    • 10.1.3. Other Development Activities
    • 10.1.4. Product Profile
  • 10.2. RG 012/ SAR339375: Sanofi
    • 10.2.1. Product Description
    • 10.2.2. Clinical Development
    • 10.2.3. Other Development Activities
    • 10.2.4. Product Profile

11. Case Reports

  • 11.1. A Novel COL4A3 Mutation Causes Autosomal-Recessive Alport Syndrome in a Large Turkish Family
  • 11.2. Alport-like glomerular changes in a patient with nephrotic syndrome: report of a case
  • 11.3. Alport Syndrome with Recurrent Herpes Simplex Virus Keratitis
  • 11.4. Russian Family with X-linked Alport Syndrome and Cardiovascular Abnormalities
  • 11.5. An overlap of Alport syndrome and rheumatoid arthritis in a patient and literature review
  • 11.6. Macular Hole Surgery in Alport Syndrome
  • 11.7. Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases?
  • 11.8. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
  • 11.9. Nephropathies with a pattern of structural alterations of the glomerular basement membrane: Case study

12. Epidemiology and Patient Population

  • 12.1. Key Findings

13. Emerging Markets Total Prevalent Population of Alport Syndrome

14. Country Wise-Epidemiology of Alport Syndrome

  • 14.1. Assumptions and Rationale
  • 14.2. Latin America
    • 14.2.1. Argentina
    • 14.2.2. Brazil
    • 14.2.3. Colombia
    • 14.2.4. Mexico
  • 14.3. Middle East and Europe
    • 14.3.1. Russia
    • 14.3.2. Saudi Arabia
    • 14.3.3. Turkey
    • 14.3.4. United Arab Emirates (UAE)
  • 14.4. Asia
    • 14.4.1. China
    • 14.4.2. Taiwan

15. Alport Syndrome: 10 Emerging Markets Analysis

  • 15.1. Key Findings
  • 15.2. Market Size of Alport Syndrome in emerging markets
    • 15.2.1. Total Market Size of Alport Syndrome
    • 15.2.2. Market Size of Alport Syndrome by therapies

16. Latin America: Market Outlook

  • 16.1. Argentina Market Size
    • 16.1.1. Total Market Size of Alport Syndrome
    • 16.1.2. Market Size of Systemic Alport Syndrome by Therapies
  • 16.2. Brazil Market Size
    • 16.2.1. Total Market Size of Alport Syndrome
    • 16.2.2. Market Size of Systemic Alport Syndrome by Therapies
  • 16.3. Colombia Market Size
    • 16.3.1. Total Market Size of Alport Syndrome
    • 16.3.2. Market Size of Systemic Alport Syndrome by Therapies
  • 16.4. Mexico Market Size
    • 16.4.1. Total Market Size of Alport Syndrome
    • 16.4.2. Market Size of Systemic Alport Syndrome by Therapies

17. Middle East and Europe: Market Outlook

  • 17.1. Russia Market Size
    • 17.1.1. Total Market Size of Alport Syndrome
    • 17.1.2. Market Size of Systemic Alport Syndrome by Therapies
  • 17.2. Saudi Arabia Market Size
    • 17.2.1. Total Market Size of Alport Syndrome
    • 17.2.2. Market Size of Systemic Alport Syndrome by Therapies
  • 17.3. Turkey Market Size
    • 17.3.1. Total Market Size of Alport Syndrome
    • 17.3.2. Market Size of Systemic Alport Syndrome by Therapies
  • 17.4. United Arab Emirates (UAE)
    • 17.4.1. Total Market Size of Alport Syndrome
    • 17.4.2. Market Size of Systemic Alport Syndrome by Therapies

18. Asia: Market Outlook

  • 18.1. China Market Size
    • 18.1.1. Total Market Size of Alport Syndrome
    • 18.1.2. Market Size of Systemic Alport Syndrome by Therapies
  • 18.2. Taiwan Market Size
    • 18.2.1. Total Market Size of Alport Syndrome
    • 18.2.2. Market Size of Systemic Alport Syndrome by Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: List of drugs for the treatment of Alport syndrome
  • Table 2: Organizations contributing toward Alport Syndrome
  • Table 3: Key Cross Competitors
  • Table 4: Bardoxolone Methyl, Clinical Trial Description, 2019
  • Table 5: Bardoxolone Methyl, Safety and Efficacy Description
  • Table 6: Bardoxolone Methyl, Drug Profile
  • Table 7: RG 012, Clinical Trial Description, 2019
  • Table 8: RG012, Preclinical Results
  • Table 9: RG 012, Drug Profile
  • Table 10: Total Prevalent Patient Population of Alport Syndrome in 10 emerging markets (2017-2028)
  • Table 11: Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
  • Table 12: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
  • Table 13: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
  • : Diagnosed cases of Alport Syndrome in Argentina (2017-2028)
  • Table 14: Treatable cases of Alport Syndrome in Argentina (2017-2028)
  • Table 15: Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
  • Table 16: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
  • Table 17 : Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
  • Table 18: Diagnosed cases of Alport Syndrome in Brazil (2017-2028)
  • Table 19: Treatable cases of Alport Syndrome in Brazil (2017-2028)
  • Table 20: Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
  • Table 21: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
  • Table 22: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
  • Table 23: Diagnosed cases of Alport Syndrome in Colombia (2017-2028)
  • : Treatable cases of Alport Syndrome in Colombia (2017-2028)
  • Table 24: Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
  • Table 25: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
  • Table 26: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
  • Table 27: Diagnosed cases of Alport Syndrome in Mexico (2017-2028)
  • Table 28: Treatable cases of Alport Syndrome in Mexico (2017-2028)
  • Table 29: Total Prevalent Population of Alport Syndrome in Russia (2017-2028)
  • Table 30: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
  • Table 31: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
  • Table 32: Diagnosed cases of Alport Syndrome in Russia (2017-2028)
  • Table 33: Treatable cases of Alport Syndrome in Russia (2017-2028)
  • Table 34: Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 35: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 36: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 37: Diagnosed cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 38: Treatable cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • : Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
  • Table 39: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
  • Table 40: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
  • Table 41: Diagnosed cases of Alport Syndrome in Turkey (2017-2028)
  • Table 42: Treatable cases of Alport Syndrome in Turkey (2017-2028)
  • Table 43: Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
  • Table 44: Total Prevalent Population Based on Clinical Types of Alport Syndrome in UAE (2017-2028)
  • Table 45: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in UAE (2017-2028)
  • Table 46: Diagnosed cases of Alport Syndrome in UAE (2017-2028)
  • Table 47: Treatable cases of Alport Syndrome in UAE (2017-2028)
  • Table 48: Total Prevalent Population of Alport Syndrome in China (2017-2028)
  • Table 49: Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
  • Table 50: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
  • Table 51: Diagnosed cases of Alport Syndrome in China (2017-2028)C
  • Table 52: Treatable cases of Alport Syndrome in China (2017-2028)
  • Table 53: Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
  • Table 54: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
  • Table 55: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
  • Table 56: Diagnosed cases of Alport Syndrome in Taiwan (2017-2028)
  • Table 57: Treatable cases of Alport Syndrome in Taiwan (2017-2028)
  • Table 58: 10 Emerging Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Table 59: 10 Emerging Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Table 60: Argentina Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 61: Argentina Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 62: Brazil Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 63: Brazil Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 64: Colombia Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 65: Colombia Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 66: Mexico Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 67: Mexico Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 68: Russia Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 69: Russia Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 70: Saudi Arabia Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 71: Saudi Arabia Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 72: Turkey Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 73: Turkey Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 74: The UAE Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 75: The UAE Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 76: China Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 77: China Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)
  • Table 78: Taiwan Market Size of Alport Syndrome in USD Million (2017-2028)
  • Table 79: Taiwan Market Size of Alport Syndrome by Therapies in USD Million ( 2017-2028)

List of Figures

  • Figure 1 Total Prevalent Population of Alport Syndrome in the emerging markets (2017)
  • Figure 2 Total Prevalent Population of Alport Syndrome in the emerging markets (2028)
  • Figure 3 Total Market Share (%) Distribution of Alport Syndrome in 2017
  • Figure 4 Total Market Share (%) Distribution of Alport Syndrome in 2028
  • Figure 5 A frozen human kidney section stained in red for COL4A4, representing the α-3 α-4 α-5(IV) network
  • Figure 6 XLAS inheritance pattern (affected father)
  • Figure 7 XLAS inheritance pattern (affected mother)
  • Figure 8 ARAS inheritance pattern
  • Figure 9 ADAS inheritance pattern
  • Figure 10 Clinical manifestations
  • Figure 11 Clinical presentation in Alport syndrome and the potential effect of treatment
  • Figure 12 Fundus examination of the eye demonstrating peri-macular flecks
  • Figure 13 Vesicle-like lesions in PPCD
  • Figure 14 Normal and Alport glomerular filtration barriers
  • Figure 15 Potential mechanisms underlying chronic renal disease occurring in Alport syndrome
  • Figure 16 Indications for genetic testing in Alport syndrome
  • Figure 17 An approach to diagnose Alport syndrome
  • Figure 18 Medications for Alport Syndrome
  • Figure 19 Therapeutic targets in Alport syndrome
  • Figure 20 Treatment Algorithm for Alport Syndrome
  • Figure 21 Unmet Needs of Alport Syndrome
  • Figure 22 Mechanism of action of Bardoxolone Methyl
  • Figure 23 Study Design: CARDINAL
  • Figure 24 Mechanism of action of RG 012
  • Figure 25 Total Prevalent Population of Alport Syndrome in 10 emerging markets (2017-2028)
  • Figure 26 Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
  • Figure 27 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
  • Figure 28 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
  • Figure 29 Diagnosed Cases of Alport Syndrome in Argentina (2017-2028)
  • Figure 30 Treatable Cases of Alport Syndrome in Argentina (2017-2028)
  • Figure 31 Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
  • Figure 32 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
  • Figure 33 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
  • Figure 34 Diagnosed Cases of Alport Syndrome in Brazil (2017-2028)
  • Figure 35 Treatable Cases of Alport Syndrome in Brazil (2017-2028)
  • Figure 36 Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
  • Figure 37 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
  • Figure 38 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
  • Figure 39 Diagnosed Cases of Alport Syndrome in Colombia (2017-2028)
  • Figure 40 Treatable Cases of Alport Syndrome in Colombia (2017-2028)
  • Figure 41 Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
  • Figure 42 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
  • Figure 43 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
  • Figure 44 Diagnosed Cases of Alport Syndrome in Mexico (2017-2028)
  • Figure 45 Treatable Cases of Alport Syndrome in Mexico (2017-2028)
  • Figure 46 Total Prevalent Patient Population of Alport Syndrome in Russia (2017-2028)
  • Figure 47 Total Prevalent Patient Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
  • Figure 48 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
  • Figure 49 Diagnosed Cases of Alport Syndrome in Russia (2017-2028)
  • Figure 50 Treatable Cases of Alport Syndrome in Russia (2017-2028)
  • Figure 51 Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 52 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 53 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 54 Diagnosed Cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 55 Treatable Cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 56 Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
  • Figure 57 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
  • Figure 58 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
  • Figure 59 Diagnosed Cases of Alport Syndrome in Turkey (2017-2028)
  • Figure 60 Treatable Cases of Alport Syndrome in Turkey (2017-2028)
  • Figure 61 Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
  • Figure 62 Total Prevalent Population Based on Clinical Types of Alport Syndrome in the UAE (2017-2028)
  • Figure 63 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in the UAE (2017-2028)
  • Figure 64 Diagnosed Cases of Alport Syndrome in the UAE (2017-2028)
  • Figure 65 Treatable Cases of Alport Syndrome in the UAE (2017-2028)
  • Figure 66 Total Prevalent Population of Alport Syndrome in China (2017-2028)
  • Figure 67 Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
  • Figure 68 Diagnosed Cases of Alport Syndrome in China (2017-2028)
  • Figure 69 Treatable Cases of Alport Syndrome in China (2017-2028)
  • Figure 70 Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
  • Figure 71 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
  • Figure 72 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
  • Figure 73 Diagnosed Cases of Alport Syndrome in Taiwan (2017-2028)
  • Figure 74 Treatable Cases of Alport Syndrome in Taiwan (2017-2028)
  • Figure 75 7 Major Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 76 10 Emerging Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 77 Argentina Market Size of Alport Syndrome in USD Million ( 2017-2028)c
  • Figure 78 Argentina Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 79 Brazil Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 80 Brazil Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 81 Colombia Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 82 Colombia Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 83 Mexico Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 84 Mexico Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 85 Russia Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 86 Russia Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 87 Saudi Arabia Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 88 Saudi Arabia Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 89 Turkey Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 90 Turkey Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 91 The UAE Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 92 The UAE Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 93 China Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 94 China Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 95 Taiwan Market Size of Alport Syndrome in USD Million ( 2017-2028)
  • Figure 96 Taiwan Market Size of Alport Syndrome by Therapies in USD Million (2017-2028)
  • Figure 97 Market Drivers
  • Figure 98 Market Barriers
  • Figure 99 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
Back to Top